(Alliance News) - GSK predicted an annual outturn at the top end of guidance, BAE Systems maintained its outlook, while Aston Martin softened its profit forecast. Here is what you need to know before ...

Shares of GSK fell to below $30 around the time of the demerger, but have since recovered to about $36. The 20% gain over 34 ...

Price Performance & Valuation Year to date, GSK’s stock has gained 4.8% compared to the industry’s 20.0% growth. The stock has also underperformed the sector and the S&P 500.

Wall Street shares last night weakened, with the S&P 500 index down 0.3% ahead of tonight’s interest rate decision and latest batch of megacap earnings. The Dow Jones Industrial Average also fell 0.5% ...

GSK and S&P 500 Performance During 2007-08 Crisis GSK stock declined from $53 in September 2007 (pre-crisis peak) to around $28 in March 2009, as the markets bottomed out, implying it lost 48% of ...

GSK GSK stock has risen 21.5% in the past six months. The consistently strong performance of the Specialty Medicines unit, regulatory and pipeline successes and an optimistic outlook for the long ...

The latest trading session saw GSK (GSK) ending at $36.19, denoting a -0.85% adjustment from its last day's close. The stock outperformed the S&P 500, which registered a daily loss of 1.47% ...

GSK is a Zacks Rank #3 (Hold) stock, with a Value Style Score of A and VGM Score of A. Shares are currently trading at a forward P/E of 8.6X for the current fiscal year compared to the Medical ...

GSK’s Price Performance, Valuation & Estimate Movement GSK stock has risen 20.1% year to date compared with an increase of 4.0% for the industry.